TESTIM (testosterone) by Teva is androgen receptor agonists [moa]. First approved in 2002.
Drug data last refreshed 3d ago
TESTIM is a transdermal testosterone gel indicated for hypogonadism and approved in 2002 as an androgen receptor agonist. It treats conditions ranging from sexual dysfunction and erectile dysfunction to sarcopenia, osteoporosis, and emerging indications including gender dysphoria and certain cancers. The drug works by binding androgen receptors to restore or supplement testosterone levels in deficient patients.
Modest Part D spending and claims indicate a mature product approaching loss of exclusivity; commercial team focus will shift to generic transition planning and defender strategies.
Androgen Receptor Agonists
Androgen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Puberty, Testosterone, and Brain Development
Worked on TESTIM at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTESTIM represents a specialized, mature androgen therapy with limited active job postings and narrow therapeutic focus. Career opportunities will center on generic transition planning, lifecycle extension via new indications or formulations, and regulatory affairs as LOE approaches.